10-K: Seer Inc. Files 10-K Report, Highlights Proteograph Product Suite and Market Strategy

Seer Inc.'s 10-K filing details the company's mission, technology, market strategy, and financial performance for the year ended December 31, 2023, emphasizing the potential of its Proteograph Product Suite.

Summary

• Seer Inc. is focused on decoding the proteome to improve human health, using its Proteograph Product Suite.
• The Proteograph uses engineered nanoparticle technology for unbiased, deep, rapid, and large-scale proteomic analysis.
• The company believes broader access to the proteome is essential for understanding its complexity and expanding end-markets.
• The global proteomics market was estimated to be approximately $27 billion in 2022, while the genomics market was estimated at $28 billion.
• The Proteograph Product Suite includes consumables, an automation instrument, and software, designed for easy use and scalability.
• The Proteograph XT assay, launched in June 2023, significantly enhanced sample throughput and improved protein group identification.
• The company shipped 23 instruments in 2023, bringing the total system shipments to 62 as of December 31, 2023.
• Seer is investing in market development activities to demonstrate the importance of large-scale proteomic data.
• The company is building its commercial infrastructure to sell and support its products directly in the United States, the European Union, and the United Kingdom.
• Seer is also expanding access to its products in other geographies through distributors.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the company highlights the potential of its technology and market opportunities, it also acknowledges significant financial losses, risks, and challenges. The company's innovative approach and strategic partnerships are positive, but the financial outlook and competitive landscape temper the overall sentiment.

Positives

• The Proteograph Product Suite is the first commercially available solution to combine unbiased, deep, rapid, and large-scale access to the proteome.
• The Proteograph provides unique insight into protein variation at the peptide level.
• The Proteograph allows for wide adoption by customers in both decentralized and centralized settings.
• The company's core technology has the potential for development of a range of products, applications, and platforms.
• The company has a capital-efficient and labor-efficient model with high operating leverage potential.
• The Proteograph is uniquely capable of generating robust, reproducible, deep, and unbiased proteomic data.
• The company has a diverse and expanding library of NP surfaces that can support the development of new products.
• The company has numerous issued patents and pending patent applications worldwide.

Negatives

• The company has a history of net losses and expects to continue to incur losses in the future.
• The company has a limited operating history, which may make it difficult to evaluate its current business and prospects.
• The company's operating results may fluctuate significantly in the future.
• The size of the markets for the Proteograph Product Suite may be smaller than estimated.
• The company is in the early stages of its commercialization plan and may not be able to commercialize the Proteograph as planned.
• The company's commercialization success depends on broad scientific and market acceptance of the Proteograph, which it may fail to achieve.
• The company relies on single suppliers for some components of the Proteograph Product Suite.
• The company has limited experience producing and supplying its products.
• The company's products could have defects or errors.
• The company faces potential risks related to the use, handling, storage, and transportation of biological samples and hazardous materials.

Risks

• The company may not be able to generate meaningful revenues or achieve and sustain profitability.
• The company may not be able to commercialize the Proteograph Product Suite as planned.
• The company may fail to improve the Proteograph or introduce compelling new products or services.
• Health epidemics such as the COVID-19 pandemic could adversely impact the company's business and operations.
• The company may be unable to obtain and maintain sufficient intellectual property protection.
• The company may be unable to identify and recruit qualified employees.
• The company may fail to maintain an effective system of internal controls.
• The company may be unable to consistently manufacture or source its SP100 automation instruments and consumables.
• The company may face potential risks related to the use, handling, storage and transportation of biological samples, hazardous materials and substances or chemicals.
• The company may face potential risks related to the collection, reuse and recycling of waste from products it manufactures and services it provides.
• The company may face potential risks related to compliance with environmental health and safety regulations.
• The company may face potential risks related to the use, handling, storage and transportation of biological samples, hazardous materials and substances or chemicals such as reagents in commercial products.
• The company may face potential risks related to the collection, reuse and recycling of waste from products it manufactures and services it provides.
• The company may face potential risks related to compliance with environmental health and safety regulations.
• The company may face potential risks related to the use, handling, storage and transportation of biological samples, hazardous materials and substances or chemicals such as reagents in commercial products.
• The company may face potential risks related to the collection, reuse and recycling of waste from products it manufactures and services it provides.
• The company may face potential risks related to compliance with environmental health and safety regulations.
• The company may face potential risks related to the use, handling, storage and transportation of biological samples, hazardous materials and substances or chemicals such as reagents in commercial products.
• The company may face potential risks related to the collection, reuse and recycling of waste from products it manufactures and services it provides.
• The company may face potential risks related to compliance with environmental health and safety regulations.

Future Outlook

The company expects to continue to incur significant losses and does not expect positive cash flows from operations for the foreseeable future. They plan to continue to invest in research and development, commercialization, and infrastructure.

Management Comments

• Our mission is to imagine and pioneer new ways to decode the biology of the proteome to improve human health.
• We believe that broader access to the proteome is essential, not only to understanding its complexity and accelerating biological insights, but also to expanding end-markets.
• We are focused on developing the market for deep, unbiased, rapid proteomics at scale by improving accessibility to our technology, growing the number of customer studies and publications, and expanding the installed base of the Proteograph across a wide variety of customer types.

Industry Context

This announcement highlights Seer's efforts to establish itself as a key player in the rapidly evolving proteomics market, leveraging its unique technology to compete with established players and emerging growth companies. The company is also positioning itself to capitalize on the convergence of genomics and proteomics, aiming to bridge the gap between genotype and phenotype.

Comparison to Industry Standards

• The document highlights that before the commercial launch of the Proteograph, the largest published deep unbiased plasma proteomics study measured at least 600 proteins on just 48 samples, while multiple customers have now completed or are planning studies with thousands of proteins across thousands of samples using the Proteograph.
• The document notes that Thermo Scientific directly compared the breadth of the Proteograph Product Suite to other unbiased proteomics methods using the same biological sample, and found that the Proteograph detected 6,033 proteins in plasma, representing a 7.5x expansion in depth of protein coverage compared to neat plasma which resulted in a depth of coverage of 767 proteins.
• The document also mentions that the unbiased workflows developed by leading proteomics labs can take weeks for sample preparation and MS measurement to reach an equivalent depth of proteomic coverage, while the Proteograph Product Suite enables rapid and large-scale proteomic sample processing in an approximately eight-hour workflow.
• The document compares the Proteograph to affinity-based approaches, noting that affinity-based approaches generally cannot differentiate between spliceforms, whereas unbiased MS-based approaches survey proteins at the peptide level, enabling differentiation between spliceforms.
• The document also compares the Proteograph to traditional, deep, unbiased proteomic approaches, noting that traditional approaches rely on complex workflows that do not scale because of the wide range of protein concentrations in biological samples with high dynamic range, while the Proteograph overcomes these limitations.

Related Party Transactions

• The company recognized revenue of $4.7 million in 2023 and $5.0 million in 2022 from PrognomiQ, a related party.

Stakeholder Impact

• Shareholders face risks related to the company's financial performance and market acceptance of its products.
• Employees are subject to the company's policies and may be affected by changes in the company's strategy and operations.
• Customers may benefit from the company's innovative technology but also face risks related to product quality and reliability.
• Suppliers and distributors may be affected by changes in the company's supply chain and commercial strategy.
• Creditors face risks related to the company's ability to repay its debts.

Next Steps

• The company plans to drive adoption of the Proteograph Product Suite.
• The company plans to invest in market development activities.
• The company plans to innovate continuously to develop and commercialize additional transformative products.
• The company plans to build its commercial infrastructure and manufacturing capabilities.
• The company plans to foster the creation of an ecosystem of customers, partners, and collaborators.
• The company plans to expand its proprietary engineered NP technology to analyze molecules beyond proteins.

Key Dates

Keywords

proteomics, proteome, nanoparticle technology, Proteograph Product Suite, genomics, biomarkers, mass spectrometry, precision medicine, drug discovery, diagnostics